First- and Second-line Therapy for Moderate-severe UC First- and Second-line Therapy for Moderate-severe UC
This study assessed the comparative efficacy and safety of different therapies as first-line and second-line agents for moderate-severe ulcerative colitis. What is the optimal regimen?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

FDA Accepts Remoxy NDA For Review
AUSTIN, Texas, March 01, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration (FDA) has determined that a New Drug Application (NDA) for Remoxy ER, the Company ’s lead drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Introduction of generic version reduces atorvastatin expenditure
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

ICER finds emicizumab offers improvements for haemophilia A
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Work hours and incomes reduced in patients with ME/CFS
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

CVD medication costs impart burden on healthcare system
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Healthcare spending higher in US but resource use similar
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Nivolumab cost effective for advanced melanoma in England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Addressing shortages and rising prices of off-patent drugs in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Pharmaceutical care program cost  effective for hypertension
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Co-payments often exceed prescription drug costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Longer breast cancer monitoring & quot;financially viable & quot; in Mexico
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

ICER updates price benchmark for PCSK9 inhibitor, alirocumab
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

ICER releases draft report on cystic fibrosis therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Telavancin can be cost saving in SA-HABP
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Counting the costs of AF management in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

NICE recommends avelumab for metastatic Merkel cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Alectinib may be cost  effective for ALK-positive NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

UK government's proposal could impact vaccination programmes
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

PCVs good value for money in Bhutan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Cetuximab and panitumumab cost  effective for mCRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Public satisfaction with NHS decreasing
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

HELP not cost effective in obese  adolescents
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

ICER's evidence-based reports set to guide US policymakers
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

CVD impacts costs in patients with T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Medication errors common and costly in England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Early dermatologist consultation for cellulitis saves costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

System-level workplace dietary intervention cost  effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Collaborative care for PTSD: better outcomes at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Comparing resource use and costs in Taiwan: LAI vs oral risperidone
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Typhoid vaccine Vi conjugate cost  effective in various settings
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Administrative costs substantial in US academic healthcare system
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Monetary values placed on caregiver tasks in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Omalizumab cost effective for chronic spontaneous urticaria
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ( “Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Rejects Celgene's NDA for Ozanimod in MS FDA Rejects Celgene's NDA for Ozanimod in MS
In a'refusal to file'letter, the FDA determined that the nonclinical and clinical pharmacology sections in the ozanimod NDA were insufficient to allow a complete review.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 28, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Bupivacaine Hydrochloride Injection, USP (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Bupivacaine Hydrochloride and Epinephrine Injection, USP (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Peginterferon alfa-2b (Sylatron) (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Sterile Water (Updated - Currently in Shortage
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Sumatriptan (Sumavel DosePro) Injection (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Diltiazem Hydrochloride (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females - Rahikainen AL, Palo JU, Haukka J, Sajantila A.
BACKGROUND: Genetic variation in efflux transporter, permeability glycoprotein (P-gp), has recently been associated with completed violent suicides and also violent suicide attempts. As depression is known to be a risk factor for suicide and many antidepre... (Source: SafetyLit)
Source: SafetyLit - February 28, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Revalidation events in Scotland
We are pleased to share a list of our upcoming revalidation events across Scotland. Come along and get answers to all the questions you have about the upcoming revalidation proces. RPS Dumfries and (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

RPS Wales calls for urgent investment in e-prescribing in Wales
A report into the prevalence ofmedication errors in England has reignited calls by RPS Wales for urgent investment and roll-out of a robust electronic prescribing system across the Welsh hospital sect (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Monovisc (High Molecular Weight Hyaluronan Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018
DUBLIN, Feb. 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, today announced that it was notified by the U.S. Food and Drug Administration (FDA) that the review of the New Drug Application (NDA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 28, 2018 Category: Drugs & Pharmacology Source Type: news

Una revisi ón de la FDA descubre que datos adicionales respaldan la posibilidad de mayor riesgo a largo plazo del antibiótico claritromicina (Biaxin) en pacientes con cardiopatías
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 27, 2018 Category: Drugs & Pharmacology Source Type: news

Una revisi ó n de la FDA descubre que datos adicionales respaldan la posibilidad de mayor riesgo a largo plazo del antibi ó tico claritromicina (Biaxin) en pacientes con cardiopat í as
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 27, 2018 Category: Drugs & Pharmacology Source Type: news

Rheumatoid arthritis potential treatment found in scorpion venom
A group of researchers have identified a component in scorpion venom that could help develop new treatments for rheumatoid arthritis, a study in theJournal of Pharmacology and Experimental Therapeutics suggests.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 27, 2018 Category: Endocrinology Source Type: news